Physician profile
Kamran Boka
NPI 1922249770
$3,150.90
in general payments reported to CMS, 2019-2025
25 companies · $1,644 in 2025
The $1,644 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $30.68 · 2021: $17.80 · 2022: $51.54 · 2023: $404 · 2024: $1,002 · 2025: $1,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,028 · Education: $22.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,028.36 |
| Education | $22.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,153.45 | 2023-2025 | Tezspire, Airsupra, Fasenra |
| Amgen INC. | $362.79 | 2023-2025 | Tezspire |
| Glaxosmithkline, LLC. | $249.82 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Abbott Laboratories | $145.99 | 2025 | 2nd Gen Centrimag Primary Console |
| Genzyme Corporation | $136.42 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $134.39 | 2024-2025 | Dupixent |
| Insmed, INC. | $132.22 | 2024-2025 | Arikayce, Brinsupri |
| Galvanize Therapeutics, INC | $115.58 | 2025 | Aliya System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.51 | 2023-2025 | Ofev, Spiriva Respimat, Jascayd |
| Merck Sharp & Dohme LLC | $90.20 | 2024-2025 | Winrevair, Keytruda |
| United Therapeutics Corporation | $86.28 | 2024-2025 | Tyvaso, Tyvaso |
| Intuitive Surgical, INC. | $51.54 | 2022 | |
| Janssen Pharmaceuticals, INC | $48.79 | 2020-2024 | Xarelto |
| Electromed, INC. | $39.49 | 2024 | Smartvest |
| Grifols USA, LLC | $39.46 | 2024-2025 | Prolastin-C Liquid |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $34.87 | 2024 | Yupelri |
| La Jolla Pharmaceutical Company | $34.39 | 2025 | Giapreza |
| Mallinckrodt Hospital Products INC. | $29.55 | 2025 | Acthar |
| Csl Behring | $29.17 | 2023 | Kcentra |
| Actelion Pharmaceuticals US, INC. | $27.74 | 2024 | Uptravi, Opsumit |
| Optinose US, INC. | $27.72 | 2024 | |
| Baxter Healthcare | $27.37 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Philips North America LLC | $20.61 | 2023 | |
| Abbvie INC. | $15.90 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.65 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamran Boka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.